VDAC1 and Parkinson disease: Like neuron‐derived MDVs, when astrocyte‐derived MDVs were evaluated in the discovery cohort, the levels of SLC1A2+ and VDAC1+ EVs were significantly decreased in both PD and AD patients (Figure 4B, Figure S1C).